Clinical Trial

Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial

Study acronym: SPARX RCT
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two different paclitaxel-coated balloons, Protégé and Agent, with each other.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-02
Trial Details
NCT Number NCT07397845
Lead Sponsor Translumina GmbH
Conditions Coronary Artery Disease, Drug Eluting Balloon, Drug Eluting Stent
Enrollment 1,380 participants
Start Date 2026-04-22
Primary Completion 2028-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-01